Hematotoxicity in Acute Lymphoblastic Leukemia Children in Maintenance Phase Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03279900|
Recruitment Status : Completed
First Posted : September 12, 2017
Last Update Posted : September 19, 2018
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||101 participants|
|Official Title:||Hematotoxicity in Acute Lymphoblastic Leukemia Children in Maintenance Phase Therapy at Cipto Mangunkusumo Hospital and Its Affecting Factors|
|Actual Study Start Date :||October 2, 2017|
|Actual Primary Completion Date :||May 16, 2018|
|Actual Study Completion Date :||July 16, 2018|
- The Incidence of hematotoxicity in acute limphoblastic leukemia children during maintenance phase therapy. [ Time Frame: october 2017 ]based on medical record data: Incidence of anemia, Neutropenia, and thrombocytopenia in acute limphoblastic leukemia children during maintenance phase therapy.
- The relationship of the incidence of hematotoxicity with influencing factors [ Time Frame: November 2017 ]The relationship of the incidence of hematotoxicity (anemia, Neutropenia, thrombocitopenia) with ALL stratification (High risk or Standard risk, as written in the medical record), nutritional status (normal or malnutrition), and albumin levels (normal or Hypoalbuminemia). The determination of nutritional status is based on body weight (Kg) and Height (Meters). Determination of nutritional status using cutoff Z score based on The growth chart of WHO 2006 for children 0-5 years, and ideal weight percentage according to Waterlow criteria for children above 5 years (recommendation of Indonesian Pediatric Association).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03279900
|Cipto Mangunkusomo hospital|
|Jakarta Pusat, Jakarta, Indonesia, 10430|
|Study Director:||Rianto Setiabudy, Professor||Departemen of Pharmacology and therapeutics, FMUI|